Prediction of the haemostatic effects of bypassing therapy using comprehensive coagulation assays in emicizumab prophylaxis-treated haemophilia A patients with inhibitors.

Furukawa, Shoko; Nogami, Keiji; Shimonishi, Naruto; Nakajima, Yuto; Matsumoto, Taisei; Shima, Midori

Furukawa, Shoko; Nogami, Keiji; Shimonishi, Naruto; Nakajima, Yuto; Matsumoto, Taisei; Shima, Midori.

Furukawa S; Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan.
Nogami K; The Course of Thrombosis and Hemostasis Molecular Pathology, Nara Medical University, Kashihara, Japan.
Shimonishi N; Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan.
Nakajima Y; Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan.
Matsumoto T; Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan.
Shima M; Chugai Pharmaceutical Co., Ltd, Tokyo, Japan.

Br J Haematol ; 190(5): 727-735, 2020 09.

Article en En | MEDLINE | ID: mdl-32162680

Asunto(s)

Anticuerpos Biespecíficos/administración & dosificación; Anticuerpos Monoclonales Humanizados/administración & dosificación; Inhibidores de Factor de Coagulación Sanguínea/sangre; Hemofilia A; Adulto; Factor VIIa/farmacología; Hemofilia A/sangre; Hemofilia A/tratamiento farmacológico; Humanos; Masculino; Persona de Mediana Edad; Proteínas Recombinantes/farmacología; Tromboelastografía

Palabras clave

bispecific antibodies; blood coagulation factor inhibitors; blood coagulation tests; haemophilia A; treatment

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Anticuerpos Biespecíficos / Inhibidores de Factor de Coagulación Sanguínea / Anticuerpos Monoclonales Humanizados / Hemofilia A Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Adult / Humans / Male / Middle aged Idioma: En Año: 2020 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google